Vertex Pharmaceuticals Stock Performance
| VRTX Stock | USD 470.87 7.05 1.48% |
Vertex Pharmaceuticals has a performance score of 7 on a scale of 0 to 100. The entity has a beta of 0.97, which indicates possible diversification benefits within a given portfolio. Vertex Pharmaceuticals returns are very sensitive to returns on the market. As the market goes up or down, Vertex Pharmaceuticals is expected to follow. Vertex Pharmaceuticals right now has a risk of 1.82%. Please validate Vertex Pharmaceuticals value at risk, kurtosis, price action indicator, as well as the relationship between the semi variance and rate of daily change , to decide if Vertex Pharmaceuticals will be following its existing price patterns.
Risk-Adjusted Performance
Fair
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Vertex Pharmaceuticals are ranked lower than 7 (%) of all global equities and portfolios over the last 90 days. In spite of fairly conflicting basic indicators, Vertex Pharmaceuticals may actually be approaching a critical reversion point that can send shares even higher in March 2026. ...more
Actual Historical Performance (%)
One Day Return 4.17 | Five Day Return 2.38 | Year To Date Return 5.7 | Ten Year Return 482.83 | All Time Return 10.5 K |
Last Split Factor 2:1 | Last Split Date 2000-08-24 |
1 | Acquisition by Sachs Bruce I of 107 shares of Vertex Pharmaceuticals subject to Rule 16b-3 | 01/15/2026 |
2 | Introducing Todoist Ramble AI That Turns Natural Speech into Structured Tasks | 01/21/2026 |
3 | Melmark Appoints Two New Members to Board of Directors | 01/27/2026 |
4 | Assessing Vertex Pharmaceuticals Valuation After Fund Exit And Setback For Journavx Pain Label | 01/29/2026 |
5 | Is Vertex Pharmaceuticals Pricing Reflect Its DCF Discount And Premium PE Ratio | 01/30/2026 |
6 | Is Trending Stock Vertex Pharmaceuticals Incorporated a Buy Now | 02/03/2026 |
7 | Patterson-UTI Energy Reports Financial Results for the Quarter Ended December 31, 2025 | 02/04/2026 |
8 | Paylocity Beats Q2 Earnings and Revenue Estimates | 02/05/2026 |
9 | Capgemini and Google Cloud expand strategic partnership to accelerate AI adoption at scale by providing trusted and secure sovereign solutions | 02/06/2026 |
| Begin Period Cash Flow | 10.4 B | |
| Total Cashflows From Investing Activities | -3.8 B |
Vertex Pharmaceuticals Relative Risk vs. Return Landscape
If you would invest 42,922 in Vertex Pharmaceuticals on November 11, 2025 and sell it today you would earn a total of 4,165 from holding Vertex Pharmaceuticals or generate 9.7% return on investment over 90 days. Vertex Pharmaceuticals is currently generating 0.1656% in daily expected returns and assumes 1.8232% risk (volatility on return distribution) over the 90 days horizon. In different words, 16% of stocks are less volatile than Vertex, and 97% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Vertex Pharmaceuticals Target Price Odds to finish over Current Price
The tendency of Vertex Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move above the current price in 90 days |
| 470.87 | 90 days | 470.87 | about 11.61 |
Based on a normal probability distribution, the odds of Vertex Pharmaceuticals to move above the current price in 90 days from now is about 11.61 (This Vertex Pharmaceuticals probability density function shows the probability of Vertex Stock to fall within a particular range of prices over 90 days) .
Vertex Pharmaceuticals Price Density |
| Price |
Predictive Modules for Vertex Pharmaceuticals
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Vertex Pharmaceuticals. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Vertex Pharmaceuticals' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Vertex Pharmaceuticals Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Vertex Pharmaceuticals is not an exception. The market had few large corrections towards the Vertex Pharmaceuticals' value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Vertex Pharmaceuticals, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Vertex Pharmaceuticals within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | 0.10 | |
β | Beta against Dow Jones | 0.97 | |
σ | Overall volatility | 18.37 | |
Ir | Information ratio | 0.06 |
Vertex Pharmaceuticals Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Vertex Pharmaceuticals for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Vertex Pharmaceuticals can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| The company reported the previous year's revenue of 11.02 B. Net Loss for the year was (535.6 M) with profit before overhead, payroll, taxes, and interest of 6.18 B. | |
| Vertex Pharmaceuticals currently holds about 9.77 B in cash with (492.6 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 38.06. | |
| Vertex Pharmaceuticals has a poor financial position based on the latest SEC disclosures | |
| Over 98.0% of the company outstanding shares are owned by institutional investors | |
| Latest headline from finance.yahoo.com: Capgemini and Google Cloud expand strategic partnership to accelerate AI adoption at scale by providing trusted and secure sovereign solutions |
Vertex Pharmaceuticals Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Vertex Stock often depends not only on the future outlook of the current and potential Vertex Pharmaceuticals' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Vertex Pharmaceuticals' indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 257.9 M | |
| Cash And Short Term Investments | 6.1 B |
Vertex Pharmaceuticals Fundamentals Growth
Vertex Stock prices reflect investors' perceptions of the future prospects and financial health of Vertex Pharmaceuticals, and Vertex Pharmaceuticals fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Vertex Stock performance.
| Return On Equity | 0.22 | ||||
| Return On Asset | 0.12 | ||||
| Profit Margin | 0.31 % | ||||
| Operating Margin | 0.40 % | ||||
| Current Valuation | 116.81 B | ||||
| Shares Outstanding | 253.72 M | ||||
| Price To Earning | 24.57 X | ||||
| Price To Book | 7.00 X | ||||
| Price To Sales | 10.45 X | ||||
| Revenue | 11.02 B | ||||
| Gross Profit | 6.18 B | ||||
| EBITDA | 486.3 M | ||||
| Net Income | (535.6 M) | ||||
| Cash And Equivalents | 9.77 B | ||||
| Cash Per Share | 38.06 X | ||||
| Total Debt | 1.75 B | ||||
| Debt To Equity | 0.06 % | ||||
| Current Ratio | 4.70 X | ||||
| Book Value Per Share | 68.20 X | ||||
| Cash Flow From Operations | (492.6 M) | ||||
| Earnings Per Share | 14.19 X | ||||
| Market Capitalization | 122.53 B | ||||
| Total Asset | 22.53 B | ||||
| Retained Earnings | 9.61 B | ||||
| Working Capital | 6.03 B | ||||
| Current Asset | 1.41 B | ||||
| Current Liabilities | 506.35 M | ||||
About Vertex Pharmaceuticals Performance
Evaluating Vertex Pharmaceuticals' performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if Vertex Pharmaceuticals has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Vertex Pharmaceuticals has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 258.72 | 271.66 | |
| Return On Tangible Assets | (0.02) | (0.02) | |
| Return On Capital Employed | (0.01) | (0.01) | |
| Return On Assets | (0.02) | (0.02) | |
| Return On Equity | (0.03) | (0.03) |
Things to note about Vertex Pharmaceuticals performance evaluation
Checking the ongoing alerts about Vertex Pharmaceuticals for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Vertex Pharmaceuticals help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| The company reported the previous year's revenue of 11.02 B. Net Loss for the year was (535.6 M) with profit before overhead, payroll, taxes, and interest of 6.18 B. | |
| Vertex Pharmaceuticals currently holds about 9.77 B in cash with (492.6 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 38.06. | |
| Vertex Pharmaceuticals has a poor financial position based on the latest SEC disclosures | |
| Over 98.0% of the company outstanding shares are owned by institutional investors | |
| Latest headline from finance.yahoo.com: Capgemini and Google Cloud expand strategic partnership to accelerate AI adoption at scale by providing trusted and secure sovereign solutions |
- Analyzing Vertex Pharmaceuticals' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Vertex Pharmaceuticals' stock is overvalued or undervalued compared to its peers.
- Examining Vertex Pharmaceuticals' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Vertex Pharmaceuticals' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Vertex Pharmaceuticals' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Vertex Pharmaceuticals' stock. These opinions can provide insight into Vertex Pharmaceuticals' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Vertex Stock Analysis
When running Vertex Pharmaceuticals' price analysis, check to measure Vertex Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Vertex Pharmaceuticals is operating at the current time. Most of Vertex Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Vertex Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Vertex Pharmaceuticals' price. Additionally, you may evaluate how the addition of Vertex Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.